EBioMedicine:基因表达标志可识别肺癌的侵袭性

2015-07-25 MedSci MedSci原创

EBioMedicine:基因表达标志可识别侵袭性肺癌虽然一些肺癌筛查手段可以早期识别肿瘤,但是并没有因此而影响了患者的生存率。近日,来自英国牛津大学及意大利国家癌症研究所的研究人员发现,可以通过区分不同的肿瘤类型来解释这个现象,该研究结果发表于EBioMedicine。为了能在肺癌的早期阶段便可识别,在过去的15年里,意大利研究人员使用CT检查了超过5000名重度吸烟者,目前已成功实现了这个目标




虽然一些肺癌筛查手段可以早期识别肿瘤,但是并没有因此而影响了患者的生存率。近日,来自英国牛津大学及意大利国家癌症研究所的研究人员发现,可以通过区分不同的肿瘤类型来解释这个现象,该研究结果发表于EBioMedicine。

为了能在肺癌的早期阶段便可识别,在过去的15年里,意大利研究人员使用CT检查了超过5000名重度吸烟者,目前已成功实现了这个目标。

然而,尽管可在早期阶段识别肺癌,但是并没有因此改变了患者的生存率, Dr. Jiangting Hu说道:

“如果在识别肿瘤方面做的很好,那么下一步便希望可以通过早期治疗以减少患者的死亡。但是,这种早期肿瘤的识别与患者生存率之间并无明确的关联。”

因此,Dr. Jiangting Hu及其同事开始着手于寻找肿瘤之间的的基因差异,这可能会解释为何早期发现了肿瘤有些患者得以存活而有些却不幸去世。

进展缓慢的肿瘤与侵袭性肿瘤之间基因表达不同

研究人员设想,是否这种筛查识别的多数为生长缓慢或“懒惰的”肿瘤,这些肿瘤可以通过手术切除,但是,有些患者可能存在侵袭性的肿瘤,而CT扫描并不能识别这类肿瘤的发展。

研究人员对比了52名患者的肿瘤的基因表达标志与其临床信息,如检测的年份,肿瘤的阶段以及患者是否存活。

寻找基因表达的差异是因为两个肿瘤可能存在完全相同的基因或突变,但是二者某些基因的活性水平可能存在差异,这种差异可通过观察microRNA而非DNA来发现。

研究人员发现239个基因的表达与患者的生存率相关,正如资深作者 Francesco Pezzella所解释的:
“值得注意的是,根据239个基因的表达标志可将患者分为两组,清楚地预测无病生存,同样可将“懒惰的”肿瘤在基线时期从后来筛查过程中发现的肿瘤中区别开来,而不论肿瘤处于哪个阶段,肿瘤的大小,及任何组织病理研究结果。”

另一项重要的发现是,研究人员还可根据健康组织的基因表达来辨别哪些患者病情发生了变化。也许更为引人注意的发现是,两名意大利研究人员同样发现相同患者的血液检测中可发现不同的基因表达标志。

Prof. Pezzella 说道,他们的发现证实了缓慢进展与侵袭性肿瘤之间基因表达存在差异,可据此识别高危患者。还补充道:

“下一步是寻找较短的基因标志,可使我们能够开发出更具个性化的诊断,以便更好地靶向治疗肿瘤。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-09-21 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-12-24 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-23 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-08-03 shneye

    miRNA不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-06-08 linagood
  6. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-07-27 sunyl07
  8. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1917175, encodeId=3ade191e17560, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Sep 21 19:27:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773498, encodeId=a9801e73498f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Dec 24 15:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858617, encodeId=dbda185861e6c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Jan 23 11:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34274, encodeId=7ebd342e40c, content=miRNA不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Mon Aug 03 16:07:00 CST 2015, time=2015-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997069, encodeId=7b3c199e06957, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Wed Jun 08 11:27:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348007, encodeId=2f29134800e80, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366239, encodeId=97cc136623940, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577431, encodeId=191715e743101, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606553, encodeId=4c58160655394, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 27 05:27:00 CST 2015, time=2015-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33477, encodeId=75e0334e76e, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=126b110623, createdName=ndd99, createdTime=Sat Jul 25 18:19:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-07-25 ndd99

    挺好

    0

相关资讯

ONF:如何提高非小细胞肺癌患者的服药依从性?

目的:该研究的目的在于探究癌症患者的口服药指导教育措施(在护士的指导干预下),对加强患者的化疗药相关知识并坚持服药是否有效,及其有效程度。研究中关于患者口服化疗药指导所使用的护理措施(MOATT)和教育工具已得到多国家医疗机构认可。方式:该研究为纵向、描述性、可行性研究。研究地点在一个动态胸部肿瘤疾病中心进行,该疾病中心位于波士顿的达纳法伯癌症研究所。参与人员为30位口服化疗药物埃罗替尼的肺癌患者

BBC:肺癌治疗的里程碑新发现

2015年5月30日,据BBC新闻报道的一项新近研究称,肺癌治疗可使一些患者的生存期加倍,实属里程碑式的新发现。        Nivolumab可使隐藏与人体正常防御系统之下的癌细胞无所遁形,让其接受人体免疫系统的自发处理。        该结果来自纳入582例癌症患者的研究结论,在美国临床肿瘤学

ACS指南:所有肺腺癌患者都需基因检测

ASCO最近认可了一项指南,确定了哪些肺癌患者需要进行基因检测测试评估,最显著的是陈述了所有的肺腺癌(或具有肺腺癌成分的混合肺癌)患者都应该接受表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)的检测。无论患者的性别、种族和吸烟习惯如何都应该进行上述测试。因为基因检测能帮助制定针对肺癌患者的个体化的治疗方案,并且改善晚期肺癌患者的预后”。因为EGFR靶向药物如厄罗替尼和阿法替尼,ALK靶向药

JTO:戒烟或可使肺癌患者活的更久

近日,发表在国际杂志Journal of Thoracic Oncology上的一篇研究报道中,来自帕克癌症研究所(Roswell Park Cancer Institute)的研究人员通过研究表示,戒烟或可使肺癌病人活的更久一些;帕克癌症研究所拥有独特的烟草评估和戒烟服务(TACS),其可以针对肺癌患者开展标准化的烟草使用评估服务,并且为患者提供精细化的戒烟咨询服务。 文章中,研究者对250名

ONF:哪种戒烟手册对肺癌患者家属戒烟效果棒棒哒?

目的:该研究的目的在于探索创新出一种具有性别特异性、且可以通过情感抚慰和亲情教育等相关因素,进而起到鼓励肺癌患者的相关家属成功戒烟的效果。方式:该研究为定性、描述性研究。实验地点在加拿大六个城市进行,参与人员为30名准备近期戒烟、或已经成功戒烟的肺癌患者的家属。这种戒烟手册通过采用语言和图片的形式强调家庭成员及亲属关系的重要性,并且根据戒烟者性别的不同而进行不同的讨论和指导,从而鼓励肺癌患者家属戒

PNAS:携带siRNA纳米颗粒可抑制肺癌细胞

RNA干扰(RNAi)是一种很有前途的方法,可以用来作为针对人体不同疾病(如癌症)的治疗策略。然而,在体内,如何将小分子siRNA转移到肿瘤或者癌细胞聚集的区域一直是很难的课题。通过一种高效的自组装系统,来自美国哈佛医学院和中国四川大学华西医学院的课题组,发展了一套独特的纳米颗粒平台,通过由固体多聚阳离子脂类和脂类-多聚乙二醇构成的分子外壳,包裹着小分子siRNA的运输系统。 在465个非小细胞